<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39386278</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1188-4169</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Canada communicable disease report = Releve des maladies transmissibles au Canada</Title><ISOAbbreviation>Can Commun Dis Rep</ISOAbbreviation></Journal><ArticleTitle>Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>374</EndPage><MedlinePgn>365-374</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14745/ccdr.v50i10a05</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In response to the COVID-19 pandemic, a new oral antiviral called nirmatrelvir-ritonavir (Paxlovid<sup>TM</sup>) was authorized for use in Canada in January 2022. <i>In vitro</i> studies have reported mutations in M<sup>pro</sup> protein that may be associated with the development of nirmatrelvir resistance.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To survey the prevalence, relevance and temporal patterns of M<sup>pro</sup> mutations among SARS-CoV-2 Omicron lineages in Ontario, Canada.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 93,082 M<sup>pro</sup> gene sequences from December 2021 to September 2023 were analyzed. Reported <i>in vitro</i> M<sup>pro</sup> mutations were screened against our database using in-house data science pipelines to determine the nirmatrelvir resistance. Negative binomial regression was conducted to analyze the temporal trends in M<sup>pro</sup> mutation counts over the study time period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A declining trend was observed in non-synonymous mutations of M<sup>pro</sup> sequences, showing a 7.9% reduction (95% CI: 6.5%-‬9.4%; <i>p</i>&lt;0.001) every 30 days. The P132H was the most prevalent mutation (higher than 95%) in all Omicron lineages. <i>In vitro</i> nirmatrelvir-resistant mutations were found in 3.12% (n=29/929) Omicron lineages with very low counts, ranging from one to 19. Only two mutations, A7T (n=19) and M82I (n=9), showed temporal presence among the BA.1.1 in 2022 and the BQ.1.2.3 in 2022, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The observations suggest that, as of September 2023, no significant or widespread resistance to nirmatrelvir has developed among SARS-CoV-2 Omicron variants in Ontario. This study highlights the importance of creating automated monitoring systems to track the emergence of nirmatrelvir-resistant mutations within the SARS-CoV-2 virus, utilizing genomic data generated in real-time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duvvuri</LastName><ForeName>Venkata</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shire</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isabel</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braukmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchand-Austin</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eshaghi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandukwala</LastName><ForeName>Hina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Nobish</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivaraman</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Hadia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cronin</LastName><ForeName>Kirby</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Ashleigh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zygmunt</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine, University of Ottawa, Ottawa, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramotar</LastName><ForeName>Karam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kus</LastName><ForeName>Julianne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasso</LastName><ForeName>Maan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbeil</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gubbay</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Commun Dis Rep</MedlineTA><NlmUniqueID>9303729</NlmUniqueID><ISSNLinking>1188-4169</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Ontario</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">genomic surveillance</Keyword><Keyword MajorTopicYN="N">in vitro resistant mutations</Keyword><Keyword MajorTopicYN="N">main protease gene (Mpro)</Keyword><Keyword MajorTopicYN="N">nirmatrelvir-ritonavir</Keyword></KeywordList><CoiStatement>Competing interests JB Gubbay is a paid consultant scientific editor for GIDEON Informatics, Inc., which is unrelated to the current work. All other authors have no competing interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386278</ArticleId><ArticleId IdType="pmc">PMC11464099</ArticleId><ArticleId IdType="doi">10.14745/ccdr.v50i10a05</ArticleId><ArticleId IdType="pii">501005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. Washington, DC: FDA; 2021. [Accessed 2023 Aug 21]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) - Center for Drug Evaluation and Research (CDER) Review. Silver Springs, MD: USDHHS; 2021. [Accessed 2023 Aug 21]. https://www.fda.gov/media/155194/download</Citation></Reference><Reference><Citation>Pfizer Labs. Fact sheet for healthcare providers: Emergency Use Authorization for PaxlovidTM. New York, NY: Pfizer; 2024. [Accessed 2023 Aug 26]. https://www.fda.gov/media/155050/download</Citation></Reference><Reference><Citation>Health Canada. Health Canada authorizes PAXLOVIDTM for patients with mild to moderate COVID-19 at high risk of developing serious disease. Ottawa, ON: HC; 2022. [Accessed 2023 Aug 23]. https://www.canada.ca/en/health-canada/news/2022/01/health-canada-authorizes-paxlovidtm-for-patients-with-mild-to-moderate-covid-19-at-high-risk-of-developing-serious-disease.html</Citation></Reference><Reference><Citation>Ontario Health. Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19. [Accessed 2024 Jul 7]. https://www.ontariohealth.ca/sites/ontariohealth/files/Recommendations-for-Antiviral-Therapy-for-Adults-with-Mild-to-Moderate-COVID-19.pdf</Citation></Reference><Reference><Citation>Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014;281(18):4085–96. 10.1111/febs.12936</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12936</ArticleId><ArticleId IdType="pmc">PMC7163996</ArticleId><ArticleId IdType="pubmed">25039866</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300(5626):1763–7. 10.1126/science.1085658</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RS, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374(6575):1586–93. 10.1126/science.abl4784</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators . Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022;386(15):1397–408. 10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 2022;400(10359):1213–22. 10.1016/S0140-6736(22)01586-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01586-0</ArticleId><ArticleId IdType="pmc">PMC9539539</ArticleId><ArticleId IdType="pubmed">36216007</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis 2023;23(6):696–705. 10.1016/S1473-3099(23)00011-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00011-7</ArticleId><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, Paccione M, Deckert J, Sandmann D, Gerhart JL, Hagen MB. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep 2022;71(48):1531–7. 10.15585/mmwr.mm7148e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7148e2</ArticleId><ArticleId IdType="pmc">PMC9721144</ArticleId><ArticleId IdType="pubmed">36454693</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz KL, Wang J, Tadrous M, Langford BJ, Daneman N, Leung V, Gomes T, Friedman L, Daley P, Brown KA. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19. CMAJ 2023;195(6):E220–6. 10.1503/cmaj.221608</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.221608</ArticleId><ArticleId IdType="pmc">PMC9928441</ArticleId><ArticleId IdType="pubmed">36781188</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell R, Lee D, Pelude L, Comeau J, Conly J, Ellis C, Ellison J, Embil J, Evans G, Johnston L, Johnstone J, Katz K, Kibsey P, Lee B, Lefebvre MA, Longtin Y, McGeer A, Mertz D, Minion J, Smith S, Srigley J, Suh K, Tomlinson J, Wong A, Thampi N, Frenette C. Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program. Can Commun Dis Rep 2023;49(7-8):351–7. 10.14745/ccdr.v49i78a07</Citation><ArticleIdList><ArticleId IdType="doi">10.14745/ccdr.v49i78a07</ArticleId><ArticleId IdType="pmc">PMC10917417</ArticleId><ArticleId IdType="pubmed">38455882</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Mossman K, Grandvaux N. Molecular Determinants of SARS-CoV-2 Variants. Trends Microbiol 2021;29(10):871–3. 10.1016/j.tim.2021.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8313503</ArticleId><ArticleId IdType="pubmed">34373192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LM, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. ACS Cent Sci 2023;9(8):1658–69. 10.1021/acscentsci.3c00538</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.3c00538</ArticleId><ArticleId IdType="pmc">PMC10451032</ArticleId><ArticleId IdType="pubmed">37637734</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv 2023;9(13):eade8778. 10.1126/sciadv.ade8778</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.ade8778</ArticleId><ArticleId IdType="pmc">PMC10058310</ArticleId><ArticleId IdType="pubmed">36989354</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 2023;613(7944):558–64. 10.1038/s41586-022-05514-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang Y, Solanki K, Atre R, Lavrijsen M, Pan Q, Baig MS, Li P. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. Antiviral Res 2023;211:105555. 10.1016/j.antiviral.2023.105555</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105555</ArticleId><ArticleId IdType="pmc">PMC9925195</ArticleId><ArticleId IdType="pubmed">36791846</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350(10):1023–35. 10.1056/NEJMra025195</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra025195</ArticleId><ArticleId IdType="pubmed">14999114</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Ontario. Impact of SARS-CoV-2 Main Protease Mutations on Nirmatrelvir/Ritonavir (Paxlovid) Resistance. Toronto, ON: PHO; 2022. [Accessed 2023 Aug 23]. https://www.publichealthontario.ca/-/media/Documents/nCoV/ipac/2022/06/sars-cov2-protease-mutations-paxlovid-resistance.pdf?sc_lang=en</Citation></Reference><Reference><Citation>Public Health Ontario. Coronavirus Disease 2019 (COVID-19) - Variant of Concern Screening and Whole Genome Sequencing Surveillance. Toronto, ON: PHO; 2022. [Accessed 2023 Oct 9]. https://www.publichealthontario.ca/en/Laboratory-Services/Test-Information-Index/COVID-19-VoC</Citation></Reference><Reference><Citation>Ontario Ministry of Health. COVID-19 Provincial Testing Guidance. Toronto, ON: MOH; 2023. [Accessed 2023 Oct 9]. https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/covid-19_provincial_testing_guidance.pdf</Citation></Reference><Reference><Citation>Government of Ontario. Updated Eligibility for PCR Testing and Case and Contact Management Guidance in Ontario. Toronto, ON: Government of Ontario; 2021. [Accessed 2023 Oct 23]. https://news.ontario.ca/en/backgrounder/1001387/updated-eligibility-for-pcr-testing-and-case-and-contact-management-guidance-in-ontario</Citation></Reference><Reference><Citation>Kneller DW, Phillips G, O’Neill HM, Jedrzejczak R, Stols L, Langan P, Joachimiak A, Coates L, Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun 2020;11(1):3202. 10.1038/s41467-020-16954-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16954-7</ArticleId><ArticleId IdType="pmc">PMC7314768</ArticleId><ArticleId IdType="pubmed">32581217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett 2022;62:128629. 10.1016/j.bmcl.2022.128629</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2022.128629</ArticleId><ArticleId IdType="pmc">PMC8856729</ArticleId><ArticleId IdType="pubmed">35182772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JT, Yang Q, Gribenko A, Perrin BS Jr, Zhu Y, Cardin R, Liberator PA, Anderson AS, Hao L. Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid. MBio 2022;13(4):e0086922. 10.1128/mbio.00869-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00869-22</ArticleId><ArticleId IdType="pmc">PMC9426535</ArticleId><ArticleId IdType="pubmed">35862764</ArticleId></ArticleIdList></Reference><Reference><Citation>Arutyunova E, Khan MB, Fischer C, Lu J, Lamer T, Vuong W, van Belkum MJ, McKay RT, Tyrrell DL, Vederas JC, Young HS, Lemieux MJ. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer. J Mol Biol 2021;433(13):167003. 10.1016/j.jmb.2021.167003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167003</ArticleId><ArticleId IdType="pmc">PMC8061786</ArticleId><ArticleId IdType="pubmed">33895266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SA, Arutyunova E, Lu J, Khan MB, Rut W, Zmudzinski M, Shahbaz S, Iyyathurai J, Moussa EW, Turner Z, Bai B, Lamer T, Nieman JA, Vederas JC, Julien O, Drag M, Elahi S, Young HS, Lemieux MJ. SARS-CoV-2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. ACS Cent Sci 2023;9(4):696–708. 10.1021/acscentsci.3c00054</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.3c00054</ArticleId><ArticleId IdType="pmc">PMC10042146</ArticleId><ArticleId IdType="pubmed">37122453</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Hong SJ, Sheng J, Bahari F, Culbertson B, Atanaki FF, Aditham AK, Kratz AF, Luck MI, Tian R, Goff SP, Montazeri H, Sabo Y, Ho DD, Chavez A. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Cell Host Microbe 2022;30(10):1354–1362.e6. 10.1016/j.chom.2022.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.08.003</ArticleId><ArticleId IdType="pmc">PMC9365866</ArticleId><ArticleId IdType="pubmed">36029764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020;368(6489):409–12. 10.1126/science.abb3405</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip JD, Wing-Ho Chu A, Chan WM, Cheuk-Ying Leung R, Umer Abdullah SM, Sun Y, Kai-Wang To K. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. EBioMedicine 2023;91:104559. 10.1016/j.ebiom.2023.104559</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104559</ArticleId><ArticleId IdType="pmc">PMC10101811</ArticleId><ArticleId IdType="pubmed">37060743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Gammeltoft KA, Ryberg LA, Pham LV, Tjørnelund HD, Binderup A, Duarte Hernandez CR, Fernandez-Antunez C, Offersgaard A, Fahnøe U, Peters GH, Ramirez S, Bukh J, Gottwein JM. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci Adv 2022;8(51):eadd7197. 10.1126/sciadv.add7197</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.add7197</ArticleId><ArticleId IdType="pmc">PMC9770952</ArticleId><ArticleId IdType="pubmed">36542720</ArticleId></ArticleIdList></Reference><Reference><Citation>Greasley SE, Noell S, Plotnikova O, Ferre R, Liu W, Bolanos B, Fennell K, Nicki J, Craig T, Zhu Y, Stewart AE, Steppan CM. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem 2022;298(6):101972. 10.1016/j.jbc.2022.101972</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101972</ArticleId><ArticleId IdType="pmc">PMC9023115</ArticleId><ArticleId IdType="pubmed">35461811</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilmann E, Costacurta F, Moghadasi SA, Ye C, Pavan M, Bassani D, Volland A, Ascher C, Weiss AK, Bante D, Harris RS, Moro S, Rupp B, Martinez-Sobrido L, von Laer D. SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci Transl Med 2023;15(678):eabq7360. 10.1126/scitranslmed.abq7360</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq7360</ArticleId><ArticleId IdType="pmc">PMC9765458</ArticleId><ArticleId IdType="pubmed">36194133</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Ontario. Weekly Epidemiologic Summary: SARS-CoV-2 Whole Genome Sequencing in Ontario, October 16, 2023. Toronto, ON: PHO; 2023. [Accessed 2023 Oct 22]. https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?rev=66a6cdcde04046b0abb44b0eaf7d648f&amp;sc_lang=en</Citation></Reference><Reference><Citation>Sjaarda CP, Lau L, Simpson JT, Fattouh R, Biondi MJ, Maguire F, Campigotto A, Feng Y, Tozer K, Wong H, Sung WW, Kim S, Marshall CR, Sheth PM, Kozak R. Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023. JAMA Netw Open 2023;6(7):e2324963. 10.1001/jamanetworkopen.2023.24963</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.24963</ArticleId><ArticleId IdType="pmc">PMC10362469</ArticleId><ArticleId IdType="pubmed">37477915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>